SUMMARY
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease of the motor nervous system. We show using multi-electrode array and patch clamp recordings that hyperexcitability detected by clinical neurophysiological studies of ALS patients is recapitulated in induced pluripotent stem cell-derived motor neurons from ALS patients harboring superoxide dismutase 1 (SOD1), C9orf72 and fused-in-sarcoma mutations. Motor neurons produced from a genetically corrected, but otherwise isogenic, SOD1+/+ stem cell line do not display the hyperexcitability phenotype. SOD1A4V/+ ALS patient-derived motor neurons have reduced delayed-rectifier potassium current amplitudes relative to control-derived motor neurons, a deficit that may underlie their hyperexcitability. The Kv7 channel activator retigabine both blocks the hyperexcitability and improves motor neuron survival in vitro when tested in SOD1 mutant ALS cases. Therefore, electrophysiological characterization of human stem cell-derived neurons can reveal disease-related mechanisms and identify therapeutic candidates.
Summary
Although many distinct mutations in a variety of genes are known to cause Amyotrophic Lateral Sclerosis (ALS), it remains poorly understood how they selectively impact motor neuron biology and whether they converge on common pathways to cause neuronal degeneration. Here, we have combined reprogramming and stem cell differentiation approaches with genome engineering and RNA sequencing to define the transcriptional and functional changes that are induced in human motor neurons by mutant SOD1. Mutant SOD1 protein induced a transcriptional signature indicative of increased oxidative stress, reduced mitochondrial function, altered sub-cellular transport as well as activation of the ER stress and unfolded protein response pathways. Functional studies demonstrated that these pathways were perturbed in a manner dependent on the SOD1 mutation. Finally, interrogation of stem cell-derived motor neurons produced from ALS patients harboring a repeat expansion in C9orf72 indicates at least a subset of these changes are more broadly conserved in ALS.
Reprogramming somatic cells from one cell fate to another can generate specific
neurons suitable for disease modeling. To maximize the utility of patient-derived neurons,
they must model not only disease-relevant cell classes but also the diversity of neuronal
subtypes found in vivo and the pathophysiological changes that underlie
specific clinical diseases. Here, we identify five transcription factors that reprogram
mouse and human fibroblasts into noxious stimulus-detecting (nociceptor) neurons that
recapitulate the expression of quintessential nociceptor-specific functional receptors and
channels found in adult mouse nociceptor neurons as well as native subtype diversity.
Moreover, the derived nociceptor neurons exhibit TrpV1 sensitization to the inflammatory
mediator prostaglandin E2 and the chemotherapeutic drug oxaliplatin, modeling the inherent
mechanisms underlying inflammatory pain hypersensitivity and painful chemotherapy-induced
neuropathy. Using fibroblasts from patients with familial dysautonomia (hereditary sensory
and autonomic neuropathy type III), we show that the technique can reveal novel aspects of
human disease phenotypes in vitro.
In the article originally published online on April 2, 2014, Stefania Di Costanzo's name was mistakenly spelled as Stefania Dicostanza. The correction has now been made to the author list above and to the original article online. Additionally, the authors have acquired a Sequencing Read Archive (SRA) accession number for the whole-genome sequencing of the lines used as a control for the effects of gene targeting. Reads are available under SRA project number SRP041050.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.